[go: up one dir, main page]

NO20081721L - Stabil fast formulering av sertindol - Google Patents

Stabil fast formulering av sertindol

Info

Publication number
NO20081721L
NO20081721L NO20081721A NO20081721A NO20081721L NO 20081721 L NO20081721 L NO 20081721L NO 20081721 A NO20081721 A NO 20081721A NO 20081721 A NO20081721 A NO 20081721A NO 20081721 L NO20081721 L NO 20081721L
Authority
NO
Norway
Prior art keywords
sertindole
solid formulation
stable solid
pharmaceutical composition
relates
Prior art date
Application number
NO20081721A
Other languages
English (en)
Inventor
Ken Liljegren
Flemming Enok Olsen
Anne Ravnholdt Christensen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20081721L publication Critical patent/NO20081721L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse vedrører en farmasøytisk sammensetning omfattende sertindol og et beskyttelsesmiddel som absorberer stråling med en bølgelengde under 400 nm. Foreliggende oppfinnelse vedrører også anvendelsen av sertindol for fremstillingen av en farmasøytisk sammensetning omfattende sertindol og et beleggingslag omfattende beskyttelsesmidlet, slik som jernoksid, forbehandlingen av schizofreni.
NO20081721A 2005-09-08 2008-04-08 Stabil fast formulering av sertindol NO20081721L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200501255 2005-09-08
PCT/DK2006/050038 WO2007065448A1 (en) 2005-09-08 2006-09-06 Stable solid formulation of sertindole

Publications (1)

Publication Number Publication Date
NO20081721L true NO20081721L (no) 2008-04-08

Family

ID=37697999

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081721A NO20081721L (no) 2005-09-08 2008-04-08 Stabil fast formulering av sertindol

Country Status (17)

Country Link
EP (1) EP1924261A1 (no)
JP (1) JP2009507051A (no)
KR (1) KR20080042102A (no)
CN (1) CN101257906A (no)
AR (1) AR056475A1 (no)
AU (1) AU2006322460A1 (no)
BR (1) BRPI0615630A2 (no)
CA (1) CA2621866A1 (no)
EA (1) EA013167B1 (no)
IL (1) IL189541A0 (no)
MX (1) MX2008002290A (no)
NO (1) NO20081721L (no)
NZ (1) NZ565330A (no)
TW (1) TW200738239A (no)
UA (1) UA97349C2 (no)
WO (1) WO2007065448A1 (no)
ZA (1) ZA200801169B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP5591128B2 (ja) * 2009-01-29 2014-09-17 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
FR2943061B1 (fr) * 2009-03-13 2011-02-25 Rhodia Operations Composes organophosphores, systemes catalytiques comprenant ces composes et procede d'hydrocyanation ou d'hydroformylation utilisant ces systemes catalytiques
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
BR112015001101A2 (pt) 2012-07-16 2017-06-27 Fibrogen Inc formas cristalinas de um inibidor de prolil hidroxilase
KR20220164069A (ko) 2013-06-06 2022-12-12 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
CN105636585B (zh) * 2013-11-19 2020-02-07 西佳技术公司 微粉化特考韦瑞一水化物的再水化
JP2018172361A (ja) * 2016-10-14 2018-11-08 大原薬品工業株式会社 光安定性を改善した、デュロキセチンを含有する固形製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04346929A (ja) * 1991-05-22 1992-12-02 Takada Seiyaku Kk 光に安定なメシル酸ブロモクリプチン製剤
AU2587297A (en) * 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
KR20080042102A (ko) 2008-05-14
ZA200801169B (en) 2010-07-28
EP1924261A1 (en) 2008-05-28
UA97349C2 (uk) 2012-02-10
TW200738239A (en) 2007-10-16
CA2621866A1 (en) 2007-06-14
AU2006322460A1 (en) 2007-06-14
MX2008002290A (es) 2008-03-14
BRPI0615630A2 (pt) 2016-11-16
IL189541A0 (en) 2008-08-07
NZ565330A (en) 2011-06-30
WO2007065448A1 (en) 2007-06-14
AR056475A1 (es) 2007-10-10
EA013167B1 (ru) 2010-02-26
EA200800774A1 (ru) 2008-06-30
CN101257906A (zh) 2008-09-03
JP2009507051A (ja) 2009-02-19

Similar Documents

Publication Publication Date Title
NO20081721L (no) Stabil fast formulering av sertindol
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
DK1487444T3 (da) Anvendelse af pyridylamider som angiogeneseinhibitorer
UY31209A1 (es) Uso de homo y copolimeros para la estabilización de formulaciones de principios activos
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
UY28342A1 (es) Nuevos compuestos
UY29246A1 (es) Nuevos compuestos
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
SV2006002134A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis ref. 5195-sv
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
BR0313220A (pt) Pelìcula de revestimento para comprimidos e cápsulas
WO2009046842A3 (de) Thialzolderivate zur behandlung von krebs
AR039936A1 (es) Formulacion farmaceutica de liberacion modificada
CL2008003472A1 (es) Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
DE602006020295D1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application